Table 2.

The parameters considered relevant for the choice of second-line therapy and the category to which they belong.

Parameter
Number (#)	Description	Category (Therapy=T – Disease=D – Patient=P)
1	Duration of response to first-line therapy (TKI)	T
2	Selection of the first line between TKI and immunotherapy	T
3	Presence of nephrectomy in the patient	T
4	Objective of the second-line treatment	T
5	Onset of drug action	T
6	Toxicity of first-line treatment	T
7	Presence of a sarcomatoid component	D
8	Biological aggressiveness of the tumor	D
9	Prognostic class: IMDC (International Metastatic RCC Database Consortium) risk score	D, P
10	Performance status of the patient	P
11	Comorbidities (especially cardiovascular)	P
12	Immuno-oncology (I-O) characteristic of the patient	P
13	Compliance and autonomous management of therapy	P
14	Patient preference	P
15	Method of therapy administration (oral versus intravenous)	T
16	Patient motivation	P
17	Patient awareness of the therapy	P
18	Disease volume	D
19	Mechanism of action of the anticancer agent	T
20	Site of metastases	D
21	Presence of brain and liver metastases (bone excluded)	D
22	Type of progression	D
23	Symptomatology of the disease in the second line	D, P
24	Predictable need to use steroids in the short term	D, P
25	Histology	D
26	Vascular architecture in the absence of necrosis	D
27	Ratio of N/L (neutrophils/lymphocyte)	D
28	Imaging necrosis (CT)	D
29	MSI (state of instability of the microsatellites)	D